

ArcticZymes Technologies strengthens IP platform with new patent grant supporting expansion into RNA therapeutics manufacturing

Tromsø, Norway – 30 April 2026 – ArcticZymes Technologies ASA (OSE: AZT), a leading provider of specialised enzymes for advanced biomanufacturing and molecular applications, today announced the grant of a new patent supporting proprietary RNA restriction enzyme technologies for use within the therapeutic RNA manufacturing workflow, supporting the Company’s strategic expansion into the rapidly growing RNA therapeutics manufacturing market.

The newly granted patent strengthens ArcticZymes’ proprietary technology platform with the introduction of a novel RNA restriction enzyme family focused on enabling analytical, process development and manufacturing workflows for therapeutic RNA production. The protection covers key application areas relevant to RNA processing, quality control and scalable manufacturing workflows.

The global RNA therapeutics market continues to expand, driven by increasing clinical activity in mRNA, self-amplifying RNA, circular RNA and other novel modalities. As programmes progress toward late-stage development and commercialisation, demand is rising for robust, scalable and IP-secure manufacturing technologies that can improve process efficiency, product quality and regulatory confidence. ArcticZymes believes the newly granted patent enhances its ability to participate in this market through differentiated solutions that address critical workflow bottlenecks and support customers from early development through commercial manufacturing.

“This patent grant represents an important milestone in the execution of our long-term growth strategy,” said Olav Lanes, VP of Scientific Strategy and Technology at ArcticZymes Technologies. *“We are building a strong intellectual property foundation around innovative enzyme technologies for RNA therapeutics manufacturing. Our new RNA restriction enzyme is designed to solve important customer challenges across multiple workflow stages while creating long-term commercial value.”*

The Company expects the protected technology to strengthen ongoing business development discussions with prospective partners and customers active in RNA therapeutics manufacturing.

ArcticZymes will continue investing in internal innovation, targeted IP creation and strategic collaborations to expand its presence in high-growth biomanufacturing segments.

“Strong intellectual property is essential in emerging therapeutics markets,” said Michael Akoh, CEO of ArcticZymes Technologies. “Customers and partners require long-term certainty, freedom to operate and trusted suppliers. This patent further enhances our strategic position as we broaden ArcticZymes’ participation in RNA-based therapeutics manufacturing.”

ArcticZymes believes RNA therapeutics represents a significant long-term growth opportunity and remains committed to building a differentiated portfolio of enabling technologies to serve this expanding market.

To be first to receive future announcements about ArcticZymes’ new RNA enzyme portfolio, [click here](#) to register your details.

For more information, please contact:

ArcticZymes Technologies ASA

CEO, Michael B. Akoh

CFO, Børge Sørvoll

Tel: +46 (0) 70 262 37 15

Tel +47 952 90187

ir@arcticzymes.com

About ArcticZymes Technologies

ArcticZymes Technologies is a Norwegian life sciences company focused on the development, manufacturing, and commercialization of novel recombinant enzymes for use in molecular research, in vitro diagnostics (IVD), and biomanufacturing. The company has pioneered salt-active nucleases and continues to develop enzyme solutions that support efficient and reliable production of advanced therapeutics.